Goldman Sachs Downgrades Halozyme to Sell HALO faces a post-2030 royalty cliff; Goldman Sachs cuts rating to Sell with $56 target, citing long-term revenue risks. Credit: Halozyme Subscribe now Already have an account? Sign in.
